AMAG Pharmaceuticals Other Current Liabilities

The latest other current liabilities for AMAG is $150M as of September 2020. That compares with $180M in the prior-year period — down 14.2% year over year. Investors often review this figure alongside AMAG Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMAG's other current liabilities moved from $180M to $150M — a 14.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AMAG Pharmaceuticals's operating scale or balance-sheet position.

A other current liabilities figure of $150M for AMAG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AMAG's other current liabilities ($150M), review year-over-year change from $180M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack AMAG Pharmaceuticals's other current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.